DK167794B1 - Fremgangsmaade til fremstilling af en krystalform af ranitidinhydrochlorid - Google Patents

Fremgangsmaade til fremstilling af en krystalform af ranitidinhydrochlorid Download PDF

Info

Publication number
DK167794B1
DK167794B1 DK436281A DK436281A DK167794B1 DK 167794 B1 DK167794 B1 DK 167794B1 DK 436281 A DK436281 A DK 436281A DK 436281 A DK436281 A DK 436281A DK 167794 B1 DK167794 B1 DK 167794B1
Authority
DK
Denmark
Prior art keywords
ranitidine hydrochloride
ranitidine
solvent
process according
crystallization
Prior art date
Application number
DK436281A
Other languages
Danish (da)
English (en)
Other versions
DK436281A (da
Inventor
Derek Leslie Crookes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK167794(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DK436281A publication Critical patent/DK436281A/da
Application granted granted Critical
Publication of DK167794B1 publication Critical patent/DK167794B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
DK436281A 1980-10-01 1981-10-01 Fremgangsmaade til fremstilling af en krystalform af ranitidinhydrochlorid DK167794B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01
GB8031634 1980-10-01

Publications (2)

Publication Number Publication Date
DK436281A DK436281A (da) 1982-04-02
DK167794B1 true DK167794B1 (da) 1993-12-13

Family

ID=10516407

Family Applications (2)

Application Number Title Priority Date Filing Date
DK436281A DK167794B1 (da) 1980-10-01 1981-10-01 Fremgangsmaade til fremstilling af en krystalform af ranitidinhydrochlorid
DK033792A DK167923B1 (da) 1980-10-01 1992-03-12 Ranitidinhydrochlorid i form 2 og anvendelsen deraf ved fremstilling af et farmaceutisk praeparat

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK033792A DK167923B1 (da) 1980-10-01 1992-03-12 Ranitidinhydrochlorid i form 2 og anvendelsen deraf ved fremstilling af et farmaceutisk praeparat

Country Status (29)

Country Link
US (2) US4521431A (xx)
JP (1) JPS5791983A (xx)
KR (1) KR870001431B1 (xx)
AT (1) AT389696B (xx)
AU (1) AU549119B2 (xx)
BE (1) BE890574A (xx)
CA (1) CA1202638A (xx)
CH (1) CH652122A5 (xx)
CZ (1) CZ280885B6 (xx)
DE (1) DE3139134A1 (xx)
DK (2) DK167794B1 (xx)
ES (1) ES505951A0 (xx)
FR (1) FR2491067A1 (xx)
GR (1) GR72499B (xx)
HK (1) HK97985A (xx)
IE (1) IE51604B1 (xx)
IL (1) IL63968A (xx)
IT (1) IT1143237B (xx)
KE (1) KE3549A (xx)
LU (1) LU83661A1 (xx)
MY (1) MY8500747A (xx)
NL (1) NL8104482A (xx)
NZ (1) NZ198522A (xx)
PH (2) PH19489A (xx)
PT (1) PT73744B (xx)
SE (1) SE453500B (xx)
SK (1) SK403591A3 (xx)
ZA (1) ZA816809B (xx)
ZW (1) ZW24481A1 (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU45634B (sh) * 1983-07-15 1992-07-20 Richter Gedeon Vegyeszeti Gyar R.T. Postupak za dobijanje hidrohlorida 1-/2-/5-dimetilaminometil-2-(furilmetiltio)-etil /-amino-1-metilamino-2-nitroetilena
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
HU222244B1 (hu) * 1993-03-12 2003-05-28 Pharmacia & Upjohn Co. Szabad sav formájában lévő kristályos ceftiofur, ennek előállítása és ezt tartalmazó gyógyászati készítmény
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
EP0754182A1 (en) * 1994-04-08 1997-01-22 Brantford Chemicals Inc. Form 1 ranitidine hydrochloride with increased density
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
WO1995028398A1 (en) 1994-04-15 1995-10-26 The Upjohn Company Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine
IN181698B (xx) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
IN181699B (xx) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP1178041A1 (en) * 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives
DE69504156T2 (de) 1994-06-24 1998-12-24 Ranbaxy Laboratories, Ltd., New Delhi Verfahren zur Herstellung von Ranitidinhydrochlorid in der Kristallform 1
AU709057B2 (en) * 1994-11-18 1999-08-19 Pharmacia & Upjohn Company A new physically stable solid form of a fluoroquinolone
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997035853A1 (en) * 1996-03-25 1997-10-02 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
ATE207065T1 (de) 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) * 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
JP2006519162A (ja) * 2002-11-08 2006-08-24 ディオーブイ ファーマシューティカル，インク． ビシファジン塩酸塩の多形
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
KR101733180B1 (ko) * 2005-07-27 2017-05-08 뉴로반스, 인크. 신규 1-아릴-3-아자바이사이클로［3.1.0］헥산：제조 방법 및 신경 정신 질환 치료를 위한 용도
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
WO2008051465A2 (en) * 2006-10-20 2008-05-02 Scinopharm Singapore Pte, Ltd. Process for making crystalline anhydrous docetaxel
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
JP5998933B2 (ja) * 2011-06-30 2016-09-28 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN104817523B (zh) * 2015-05-26 2016-11-09 烟台市华文欣欣医药科技有限公司 一种治疗胃病的药物盐酸雷尼替丁化合物及其制备方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
SE453500B (sv) 1988-02-08
CZ280885B6 (cs) 1996-04-17
CA1202638A (en) 1986-04-01
MY8500747A (en) 1985-12-31
DK33792A (da) 1992-03-12
PH21761A (en) 1988-02-18
CZ403591A3 (en) 1994-01-19
US4672133A (en) 1987-06-09
HK97985A (en) 1985-12-13
IE51604B1 (en) 1987-01-21
ZA816809B (en) 1983-05-25
KR870001431B1 (ko) 1987-08-06
LU83661A1 (fr) 1983-06-08
ATA422281A (de) 1989-06-15
FR2491067B1 (xx) 1984-09-07
DK33792D0 (da) 1992-03-12
BE890574A (fr) 1982-04-01
PH19489A (en) 1986-05-14
AU549119B2 (en) 1986-01-16
GR72499B (xx) 1983-11-15
NZ198522A (en) 1985-07-12
AU7595581A (en) 1982-04-08
IL63968A0 (en) 1981-12-31
DK436281A (da) 1982-04-02
IL63968A (en) 1985-10-31
KE3549A (en) 1985-08-16
PT73744A (en) 1981-10-01
ES8301954A1 (es) 1983-01-01
AT389696B (de) 1990-01-10
CH652122A5 (fr) 1985-10-31
US4521431A (en) 1985-06-04
ES505951A0 (es) 1983-01-01
SK277922B6 (en) 1995-08-09
IE812287L (en) 1982-04-01
IT8149407A0 (it) 1981-10-01
NL8104482A (nl) 1982-05-03
DK167923B1 (da) 1994-01-03
DE3139134A1 (de) 1982-05-19
JPS5791983A (en) 1982-06-08
FR2491067A1 (fr) 1982-04-02
SK403591A3 (en) 1995-08-09
IT1143237B (it) 1986-10-22
ZW24481A1 (en) 1983-04-27
JPH0443070B2 (xx) 1992-07-15
PT73744B (en) 1983-10-31
KR830007070A (ko) 1983-10-14
DE3139134C2 (xx) 1990-04-19
SE8105812L (sv) 1982-04-02

Similar Documents

Publication Publication Date Title
DK167794B1 (da) Fremgangsmaade til fremstilling af en krystalform af ranitidinhydrochlorid
GB2084580A (en) Aminoalkyl Furan Derivative
US20030036559A1 (en) Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3-[2- (2-methoxyphenoxy) -ethylamino] -2-propanole process for its preparation and pharmaceutical compositions containing it
HU201901B (en) Process for producing n,n-dimethyl-1-(1-)4-chloro-phenyl(-cyclobutyl)-3-methyl-butyl-amine-hydrochloride-monohydrate
US11858894B2 (en) Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt
NO311642B1 (no) Nye modifikasjoner av 2-amino-4-(4-fluorbenzylamino)-1-etoksykarbonyl-aminobenzener, deres fremstilling og anvendelse samt legemidler inneholdende modifikasjonene
NO312514B1 (no) Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1- piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), og farmasöytisk blanding for behandling av enpsykotisk forstyrrelse
KR20070001910A (ko) 퀴놀린 화합물의 결정형 및 그의 제조 방법
JPS60260581A (ja) １−（ヒドロキシメチル）−１，６，７，１１ｂ−テトラヒドロ−２Ｈ，４Ｈ−〔１，３〕オキサジノ−または−チアジノ〔４，３−ａ〕イソキノリン誘導体
CA3215809A1 (en) New salt and solid state forms of escitalopram
RU2228931C2 (ru) Кристаллические формы 3-(2,4-дихлорбензил)-2-метил-n-(пентилсульфонил)-3h- бензимидазол-5-карбоксамида
US6172206B1 (en) Crystalline form of morphine-6-glucuronide
US5663381A (en) Process for preparing form 1 ranitidine hydrochloride
CA1198734A (en) Three polyumorphic forms of 5-[3-(2,2,2- trifluoroethyl]guanidino)-pyrazol-1-yl)-valeramide
US20110060002A1 (en) Conglomerates of tenatoprazole potassium salts
CS268837B2 (en) Method of new 1-aryloxy-dihydrobenzothiadiazinyl alkylamino-alkanes production
NO752762L (xx)
SI21067A2 (sl) Amlodipin hemimaleat

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired